The CARMA1-Bcl10 Signaling Complex Selectively Regulates JNK2 Kinase in the T Cell Receptor-Signaling Pathway  by Blonska, Marzenna et al.
Immunity
ArticleThe CARMA1-Bcl10 Signaling Complex
Selectively Regulates JNK2 Kinase
in the T Cell Receptor-Signaling Pathway
Marzenna Blonska,1 Bhanu P. Pappu,1 Reiko Matsumoto,1 Hongxiu Li,1 Bing Su,2 Demin Wang,3,4 and Xin Lin1,*
1Department of Molecular and Cellular Oncology
2Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
3The Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53226, USA
4Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, WI 53226, USA
*Correspondence: xllin@mdanderson.org
DOI 10.1016/j.immuni.2006.11.008SUMMARY
Members of the c-Jun NH2-terminal kinase
(JNK) family play crucial roles in cell activation,
differentiation, and apoptosis. Although many
studies have indicated that JNK1 and JNK2
have functional differences and redundancy,
the upstream signaling pathway that selectively
activates JNK1 or JNK2 remains unknown. In
this study, we have revealed a selective mecha-
nism of JNK activation, in which JNK2, but not
JNK1, was regulated by CARMA1, a scaffold
molecule, after stimulation of the T cell receptor
(TCR). This CARMA1-dependent regulation of
JNK2 worked through the scaffold molecule
Bcl10, which was inducibly associated with
JNK2 and served as a JNK-interacting protein
(JIP)-like scaffold to assemble the kinases
JNK2, MKK7, and TAK1. Finally, we showed
that CARMA1- and Bcl10-mediated JNK2 acti-
vation had a critical role in regulating the
amount of c-Jun protein. Together, our studies
provide genetic evidence that JNK1 and JNK2
are differentially regulated in the TCR-signaling
pathway and play different functions.
INTRODUCTION
The c-Jun NH2-terminal kinases (JNKs) are the classi-
cal stress-activated mitogen-activated protein kinases
(MAPKs) (Davis, 2000). JNK family is encoded by three
different genes: Jnk1, Jnk2, and Jnk3. JNK1 and JNK2
proteins are ubiquitously expressed, whereas the expres-
sion of JNK3 is restricted to the brain, heart, and testis
(Gupta et al., 1996; Weiss et al., 2000; Yang et al., 1997).
These isoforms differ in their interaction with transcription
factors (Gupta et al., 1996; Kallunki et al., 1994).Moreover,
the three different Jnk genes express two isoforms,
46 kDa (JNKp46) and 54 kDa (JNKp54), resulting from
the alternative splicing on their last exons, which resultsin an extra 43-residue tail at the C terminus of p54 iso-
forms (Gupta et al., 1996; Kallunki et al., 1994).
Because JNK1 and JNK2 share a high degree of the se-
quence homology, the functional redundancy of JNK1 and
JNK2 has been reported. Studies with genetically inacti-
vated JNKs have demonstrated that none of the three
JNK isoforms is necessary for normalmouse development
(Davis, 2000). However, a mouse with Jnk1 and Jnk2 dou-
ble knockout dies at embryonic day (E) 10.5, suggesting
that the biological functions of JNK1 and JNK2 isoforms
are partially redundant during embryonic development
(Kuan et al., 1999; Sabapathy et al., 1999). It has been
shown that JNK2 preferentially binds to c-Jun in unstimu-
lated cells, thereby contributing to c-Jun ubiquitination
and degradation. After stimulation, JNK2 dissociates
from c-Jun, and JNK1 phosphorylates c-Jun, resulting
in its activation and stabilization (Sabapathy et al., 2004;
Sabapathy and Wagner, 2004). Therefore, JNK2 defi-
ciency results in elevated c-Jun phosphorylation and
stability, whereas JNK1 deficiency reduces c-Jun phos-
phorylation and stability (Sabapathy et al., 2004).
Activation of JNK1 and JNK2 plays important roles in
T cell activation and differentiation (Dong et al., 1998,
2000). Stimulation of T cell receptor (TCR) induces multi-
ple signaling cascades and effectively activates both
JNK1 and JNK2. However, the signaling pathways that
lead to activation of JNK1 and JNK2 are not completely
defined. In particular, it is not clear whether JNK1 and
JNK2 are regulated through the same or different signaling
pathways after TCR stimulation. Therefore, it is important
to delineate the signaling pathway leading to the activation
of different isoforms of JNKs.
CARMA1 (CARD domain and MAGUK domain-contain-
ing protein-1) is a scaffold molecule primarily expressed in
the cells of lymphoid system (Bertin et al., 2001; Gaide
et al., 2001), which plays an essential role in antigen recep-
tor-induced NF-kB activation in T and B cells (Egawa
et al., 2003; Hara et al., 2003; Jun et al., 2003; Newton
and Dixit, 2003; Wang et al., 2002). After the stimulation
of T cell receptor and CD28 coreceptor (CD3-CD28
costimulation), protein kinase C-theta (PKCq) phosphory-
lates CARMA1, which induces CARMA1 to associate with
the downstream scaffold/adaptor molecules, Bcl10 andImmunity 26, 55–66, January 2007 ª2007 Elsevier Inc. 55
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CARMA1 and Bcl10 for JNK2 ActivationMALT1 (Matsumoto et al., 2005; Sommer et al., 2005), and
recruits these molecules into the lipid rafts of the immuno-
logical synapse (Che et al., 2004; Gaide et al., 2002; Hara
et al., 2004), leading to activation of NF-kB (Ruefli-Brasse
et al., 2003; Ruland et al., 2001, 2003; Xue et al., 2003).
Moreover, some studies suggest that CARMA1 deficiency
affects JNK activation after TCR stimulation (Gaide et al.,
2002; Hara et al., 2003). Although the mechanism by
which CARMA1 activates the NF-kB pathway is relatively
well studied, how this scaffold molecule activates the JNK
pathway remains to be determined.
In this study, we found that CARMA1-deficient Jurkat
T cells, as well as primary lymphocytes from CARMA1-
deficient mice, were defective in JNK2 activation upon
stimulation of TCR or mitogen treatment. This defect is
likely due to the defect of CARMA1-dependent complex
formation of Bcl10 with JNK2, MKK7, and TAK1. This
complex formation is required for the activation of JNK2.
In addition, the CARMA1- and Bcl10-dependent activa-
tion of JNK2 is required for the accumulation of c-Jun after
the stimulation of TCR. Thus, our results demonstrate that
the CARMA1-Bcl10 complex selectively regulates the
activation of JNK2 and modulates the amount of c-Jun
protein.
RESULTS
CARMA1-Deficient Cells Are Defective
in TCR-Induced JNK2 Phosphorylation
Studies on CARMA1-deficient mice suggests that
CARMA1 deficiency markedly decreases JNK activation
(Hara et al., 2003). However, previous studies from our
laboratory showed that JNK immunoprecipitated from
activated CARMA1-deficient Jurkat T cells could still
phosphorylate c-Jun substrate in an in vitro kinase assay
(Wang et al., 2002). To further address the role of CARMA1
in JNK activation, we analyzed JNK phosphorylation
status in CARMA1-deficient Jurkat T (JPM50.6) cells
upon TCR stimulation. Because JNK1 is predominantly a
46 kDa isoform protein (54 kDa isoform is also expressed)
and JNK2 is predominantly a 54 kDa isoform, we used an-
tibodies specific for phospho-JNK, which recognizes both
p46 and p54 kDa isoforms. We found that activation of
JNK1, as well as ERK, was comparable in Jurkat and
JPM50.6 cells after CD3-CD28 costimulation, but the ac-
tivation of JNK2 was completely abolished in JPM50.6
(Figures 1A and 1B), indicating that the activation of
JNK2 is regulated through a CARMA1-dependent mecha-
nism after TCR stimulation. Moreover, we showed that
JNK1 was phosphorylated much faster than JNK2 in
Jurkat T cells (Figure 1A), further suggesting that the acti-
vation of JNK1 and JNK2 might be regulated by distinct
signaling components. Similarly, we found that the phos-
phorylation of JNK2 was selectively defected in JPM50.6
cells treated with PMA plus ionomycin, which mimics
CD3-CD28 costimulation (Figure 1C, lanes 1–6). To
exclude the possibility that JPM50.6 cells were generally
defective in JNK2 phosphorylation, the cells were treated
with sorbitol that induces the osmotic stress leading to56 Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc.JNK activation. With this stimulation, the activation of
both JNK1 and JNK2 was comparable in Jurkat and
JPM50.6 cells (Figure 1C, lanes 7–12). Finally, to confirm
that observed defect was not due to limitation of used
phospho-JNK antibodies, we measured the amounts of
phospho-JNK2 by ELISA. As expected, CD3-CD28 and
PMA-ionomycin-induced JNK2 phosphorylation was al-
most completely abolished in JPM50.6 cells (Figure 1D).
Together, our results demonstrate that CARMA1 defi-
ciency specifically affects JNK2 activation in T cells.
Because JPM50.6 cells were generated by chemical
mutagenesis andmight contain someadditionalmutations
that affect JNK activation, we reconstituted JPM50.6 cells
with wild-type CARMA1 to confirm that CARMA1 is the es-
sential component for JNK2 activation. In these reconsti-
tuted cells, CARMA1 fully rescued CD3-CD28- or PMA-
ionomycin-induced JNK2 activation (Figure 1E). Next, we
investigated whether truncated forms of CARMA1 were
sufficient to restore JNK2 activation in JPM50.6 cells. Be-
cause CARMA1 contains an N-terminal caspase-recruit-
ment domain (CD) followed by a coiled-coil domain (C-
C), a PDZ domain, a SH3 domain, and a guanylate kinase
(GUK)-like domain (Bertin et al., 2001; Gaide et al., 2001),
we constructed two truncated forms of CARMA1: CD-CC
andDCD-CC that contained PDZ, SH3, andGUK domains
(see Figure S1A in the Supplemental Data available online).
The expression plasmids encoding truncated forms of
CARMA1 were stably transfected to JPM50.6 cells. In
contrast to wild-type CARMA1, expression of CD-CC or
DCD-CC failed to restore JNK2 activation (Figure S1B),
indicating thatCARMA1 integrity is important for regulation
of JNK2 activation. Together, these results demonstrate
that the defect of JNK2 activation is due to CARMA1
deficiency.
JNK2 Kinase Activity Is Defective in the Absence
of CARMA1
To directly compare the kinase activity of JNK isoforms in
Jurkat and JPM50.6 cells, we performed an in vitro kinase
assay after CD3-CD28 costimulation and JNK precipita-
tion. We used JNK2 antibodies, which recognize only
p54 isoform of JNK2 (Figure S2), to precipitate JNK2p54
from Jurkat or CARMA1-deficient T cells. The immunopre-
cipitated kinases were used to phosphorylate the purified
GST-c-Jun(1-79) protein in the presence of [g-32P]ATP. As
predicted, the kinase activity of JNK2p54 was detectable
in Jurkat cells (Figure 2A, lanes 5–8), but not in JPM50.6
cells (Figure 2A, lanes 13–16) after CD3-CD28 costimula-
tion. Since commercial JNK1 antibody recognizes both
p46 and p54 isoforms of JNK1 (Figure S2), we immu-
noprecipitated total JNK1 from Jurkat and CARMA1-
deficient T cells. We found that JNK1 precipitated from
Jurkat cells had relatively higher activity than JNK1 from
JPM50.6 cells (Figure 2A, lanes 1–4 and 9–12), suggesting
that both JNK1p46 and JNK1p54 may be activated in Ju-
rkat cells, but only JNK1p46 in JPM50.6 cells. Therefore,
to avoid limitation of used JNK antibodies, we overex-
pressed Flag-tagged JNK1p46, HA-tagged JNK2p54, or
Myc-tagged JNK1p54 in Jurkat and JPM50.6 cells and
Immunity
CARMA1 and Bcl10 for JNK2 ActivationFigure 1. CARMA1-Deficient JPM50.6 Cells Are Defective in TCR-Induced JNK2 Phosphorylation
(A–C) Jurkat or JPM50.6 cells (63 106/sample) were stimulated with or without anti-CD3 plus anti-CD28 (6 and 3 mg/ml, respectively) for various time
points (A, B) or with PMA (40 ng/ml) plus ionomycin (100 ng/ml) or with sorbitol (0.2 mM) (C). Whole-cell lysates were subjected to SDS-PAGE and
analyzed by immunoblot with antibodies against phospho-JNK, JNK, CARMA1, phospho-ERK, or ERK.
(D) The cells (1 3 107/sample) were treated with different stimulators for 20 min and cell lysates were analyzed with phospho-JNK2 ELISA kit. Error
bars indicate ± standard deviation in triplicate experiments.
(E) CARMA1-deficient cells (JPM50.6) or JPM50.6 cells reconstituted with CARMA1 (50.6WT) were stimulated with or without anti-CD3 (6 mg/ml) and
anti-CD28 (3 mg/ml) or PMA (40 ng) plus ionomycin (100 ng) or sorbitol (0.2 mM) for 20 min. The cell lysates were subjected to SDS-PAGE and
examined by immunoblots with antibodies against phospho-JNK, JNK, or CARMA1. Results are representative of 2–3 independent experiments.immunoprecipitated these kinaseswith anti-Flag, anti-HA,
or anti-Myc. In this experiment, JNK1p46 was effectively
activated in both Jurkat and JPM50.6 cells (Figure 2B) af-
ter CD3-CD28 costimulation. In contrast, JNK2 and long
form of JNK1 (JNK1p54) were activated only in Jurkat cells
(Figures 2C and 2D). These results demonstrate that JNK2
is completely defective whereas JNK1 could still be acti-
vated in the absence of CARMA1. Moreover, we found
that both JNK1p46 and JNK1p54 could be activated in
Jurkat cells, but only JNK1p46 in JPM50.6 cells, which
is consistent with data obtained in Figure 1 with phos-
pho-specific antibodies. It further suggests that CARMA1
deficiency specifically affects JNKp54 activation in T cells,
indicating importance of the C-terminal 43-residue tail of
JNK2 and JNK1. However, as mentioned previously,
JNK1 is expressed mainly as the 46 kDa isoform in Jurkat
T cells (Figure S2), which explains the potent activation of
JNK1 in CARMA1-deficient cells.
To further confirm the requirement of CARMA1 for
JNK2 activation, we decided to use T cells fromCARMA1-deficient mice. Primary T cell were isolated
from lymph nodes and stimulated with PMA-ionomycin.
Although this stimulation effectively activated JNK1, as
well as ERK, JNK2 activation was completely defective
in CARMA1-deficient (Card11/) cells (Figure 3A). Thus,
this result further supports the conclusion that CARMA1
is required for JNK2 activation.
Bcl10 Is Required for JNK2 Activation
Previous studies indicate that Bcl10 is a signaling compo-
nent downstream of CARMA1. After CD3-CD28 costimu-
lation, CARMA1 associates with Bcl10 and recruits this
adaptor protein into the immunological synapse, leading
to activation of downstream signaling pathways (Gaide
et al., 2002; Hara et al., 2004; Wang et al., 2004). To exam-
ine whether Bcl10 deficiency results in defective JNK2
activation, primary T cells from WT or Bcl10/ mice
were stimulated with PMA-ionomycin. Similarly to
CARMA1-deficient cells, PMA-ionomycin-induced JNK2,
but not JNK1, phosphorylation was completely abolishedImmunity 26, 55–66, January 2007 ª2007 Elsevier Inc. 57
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CARMA1 and Bcl10 for JNK2 ActivationFigure 2. JNK2 Kinase Activity Is Defective in the Absence of CARMA1
(A) In vitro kinase assay. The cells (13 107/sample) were stimulated with or without anti-CD3 plus anti-CD28, and cell lysates were precipitated with
anti-JNK1 or anti-JNK2 for 4 hr. The immunocomplexeswere incubatedwithGST-c-Jun(1-79) substrate (1 mg/sample) and [g-32P]ATP in kinase buffer
at 30C for 30 min. The phosphorylated proteins were resolved by SDS-PAGE, transferred to nylon membranes, and analyzed by autoradiography
and immunoblotting.
(B–D) Jurkat or JPM50.6 cells were transfected with FLAG-JNK1p46, HA-JNK2p54, or Myc-JNK1p54 by electroporation. 24 hr later, cells were stim-
ulated and overexpressed proteins were immunoprecipitated with anti-FLAG, anti-HA, or anti-Myc. Kinase assay was performed as described in (A).
Results are representative of 2–3 independent experiments.in Bcl10/ cells (Figure 3B). Together, these results sug-
gest that CARMA1-induced JNK2 activation is mediated
through Bcl10.
To determine whether CARMA1- and Bcl10-dependent
JNK2 activation is a T cell-specific phenomenon, primary
splenic B cells or bone marrow-derived mast cells from
CARMA1- and Bcl10-deficient mice were stimulated
with PMA-ionomycin. We found that JNK2 phosphoryla-
tion was also defective in both B cells and mast cells
from CARMA1- and Bcl10-deficient mice (Figure 3C).
Together, these results indicate that CARMA1- and
Bcl10-dependent JNK2 activation is a general mechanism
in the hematopoietic system.
Based on the above data, we hypothesized that Bcl10
might function as an adaptor protein for JNK2 in antigen
receptor-signaling pathways. If it is true, Bcl10 might
form a complex with JNK2 in activated cells. Indeed, we
successfully coprecipitated JNK2 with Bcl10 from acti-
vated Jurkat cells (Figure 4A, lanes 1–3, and Figure 4B,58 Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc.lanes 3–4), but this interaction was not observed in stimu-
lated JPM50.6 cells (Figure 4A, lanes 4–6). Moreover, we
were unable to detect the interaction between JNK1 and
Bcl10 in the same conditions (Figure 4B, lanes 1–2). These
results suggest that Bcl10 is selectively required for JNK2
activation. To test this possibility, we performed an immu-
noprecipitation experiment with two expression plasmids
encoding JNK2p54 and JNK2p46. HEK293 cells were
transfected with Myc-tagged Bcl10 expression plasmid
and cotransfected with HA-JNK2p54 or HA-JNK2p46
(Figure 4C). After 24 hr, cells were harvested and the
lysates were immunoprecipitated with HA antibody. We
found that Bcl10 was specifically associated with
JNK2p54 (Figure 4D, lane 4), but not with JNK2p46
(Figure 4D, lane 6). These results indicate that the C-termi-
nal 43-residue tail of JNK2 is required for the association
with Bcl10. To further investigate the role of Bcl10 in
JNK activation, we used a Bcl10mutant, Bcl10(L47A) (Fig-
ure 4C) that cannot oligomerize (Yan et al., 1999) to
Immunity
CARMA1 and Bcl10 for JNK2 ActivationFigure 3. Primary Cells from CARMA1 or Bcl10 Null Mice Are Defective in JNK2 Phosphorylation
(A and B) Lymph nodes T cells fromwild-type, CARMA1-deficient (Card11/) (A), orBcl10/ (B) micewere stimulated with or without PMA (20 ng/ml)
plus ionomycin (200 ng/ml).
(C) Splenic B cells and bone marrow-derived mast cells were isolated from wild-type, Card11/, and Bcl10/mice and stimulated with or without
PMA (20 ng/ml) plus ionomycin (200 ng/ml). Whole-cell lysates were subjected to SDS-PAGE and analyzed by immunoblot with indicated antibodies.
Results are representative of 2–3 independent experiments.perform the coimmunoprecipitation with JNK2p54. Inter-
estingly, Bcl10(L47A) failed to associate with JNK2p54
(Figure 4E, lane 6), suggesting that JNK2 associates only
with the activated and oligomerized Bcl10. Because
Bcl10 constitutively associates with MALT1, we also ex-
amined whether JNK2 binds to MALT1 in activated Jurkat
cells (Figure S3). Indeed, JNK2-MALT1 and JNK2-Bcl10
complexes were detectable at the same time. However,
when we overexpressed JNK2 and MALT1 constructs,
we were unable to detect the interaction between these
proteins (data not shown), suggesting that JNK2 binds
to MALT1 through Bcl10.
Bcl10 Functions as a Scaffold Molecule to Recruit
TAK1 and MKK7
Previous studies indicate that JNKs are activated by se-
quential protein phosphorylation through aMAPKmodule,
in which MAP kinase (MAPK) is activated by aMAP kinase
kinase (MAP2K), andMAP2K is regulated by aMAP kinase
kinase kinase (MAP3K) (Davis, 2000). In this cascade, JNK
is connected to its MAP2K and MAP3K through the
JNK-interacting protein, JIP (Morrison and Davis, 2003).
Because JIP family members are not expressed in lym-phocytes, it is likely that Bcl10 may function as the JIP-
like scaffold molecule for JNK2 activation in lymphocytes.
Therefore, we postulated that Bcl10 might also associate
with MAP3K and MAP2K. Although several MAP3Ks has
been reported to act as a MAP3K for JNK (Davis, 2000),
recent studies suggest that transforming growth factor-
b-activated kinase 1 (TAK1) is inducibly associated with
Bcl10 in activated B cells (Sato et al., 2005) and required
for JNK activation in innate and adaptive immune re-
sponses (Sato et al., 2005; Shim et al., 2005). Therefore,
we examined whether Bcl10 recruits TAK1 in T cells.
TAK1 was immunoprecipitated from Jurkat and JPM50.6
cells after the treatment of cells with PMA-ionomycin.
We found that Bcl10 inducibly associated with TAK1,
but not MEKK1, MEKK2, and MEKK3 (data not shown),
in Jurkat cells but not in JPM50.6 cells (Figure 5A).
Although both MKK7 and MKK4 function as MAP2Ks
for JNK (Davis, 2000), an earlier study suggests that
MKK7 is likely a kinase directly phosphorylating JNK in
activated T cells (Dong et al., 2000). Therefore, we also de-
termined whether Bcl10 could associate with MKK7. We
found Bcl10 inducibly associated with MKK7 in Jurkat
cells, but not in JPM50.6 cells (Figure 5B). To examineImmunity 26, 55–66, January 2007 ª2007 Elsevier Inc. 59
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CARMA1 and Bcl10 for JNK2 ActivationFigure 4. Bcl10 Inducibly Associates with JNK2 but Not with JNK1
(A and B) Jurkat or JPM50.6 cells (33 107/sample) were stimulated with or without PMA (40 ng/ml) plus ionomycin (100 ng/ml). The cells were lysed
and precipitated with anti-JNK2, anti-Bcl10, or anti-JNK1 (A, B). Immunocomplexes (top andmiddle) or whole-cell lysates (bottom) were subjected to
SDS-PAGE and analyzed by immunoblot with indicated antibodies.
(C) Plasmids used in overexpression experiments.
(D and E) HEK293 cells (7 3 105) were transiently transfected with 0.5 mg of expression plasmids encoding several constructs: HA-JNK2p54,
HA-JNK2p46, Myc-Bcl10 (D) or Myc-Bcl10(L47A) (E). Cells were lysed and precipitated with anti-HA. The immunocomplexes were subjected to
SDS-PAGE and analyzed by western blot with indicated antibodies. The amounts of expression of the transfected products were assessed with
anti-Myc and anti-HA immunoblots of total cell lysates. Results are representative of 2–3 independent experiments.whether TAK1, MKK7, and JNK2 associate with Bcl10 at
the same time, we performed timed immunoprecopita-
tions. We found all kinases in the complex with Bcl10 after
10 and 20 min of PMA-ionomycin treatment. However,
TAK1-Bcl10 was detected mostly after 10 min, MKK7-
Bcl10 and JNK2-Bcl10 after 20 min (Figure 5C). Together,
these data suggest that the activated Bcl10 functions as
a scaffold molecule to recruit TAK1 and MKK7 for JNK2
activation.
TCR-Induced c-Jun Accumulation Is Suppressed
in CARMA1-Deficient Cells
The transcription factor c-Jun is a critical regulator of cell-
cycle progression and a classical JNK target (Davis,
2000). Previous study suggests that JNK activation affects
the c-Jun protein amount (Sabapathy et al., 2004). There-
fore, we investigated whether the c-Jun level was altered
in CARMA1-deficient cells. Indeed, we found that basal60 Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc.amount of c-Jun was much higher in Jurkat than in
JPM50.6 cells (Figure 6A, lanes 1 and 9). Moreover,
c-Jun protein was rapidly accumulated in Jurkat T cells
upon CD3-CD28 costimulation, but this accumulation
was defective in JPM50.6 cells (Figure 6A). To exclude
the possibility that this defect of c-Jun accumulation
was due to the defective NF-kB activation in JPM50.6
cells, we used a Jurkat T cell line deficient in NEMO
(also known as IKKg), a subunit of the IKK complex, which
is completely defective in NF-kB activation. Because
NEMO-deficient Jurkat T (JM4.5.2) cells are also defective
in the expression of CD3 complex, we used PMA-CD28,
instead of CD3-CD28, to stimulate NEMO-deficient and
CARMA1-deficient cells. We found that JNK2 activation
was intact and c-Jun amount was rapidly increased in
NEMO-deficient cells upon PMA-CD28 costimulation,
but PMA-CD28 costimulation failed to activate JNK2
and to induce c-Jun accumulation in CARMA1-deficient
Immunity
CARMA1 and Bcl10 for JNK2 ActivationFigure 5. Bcl10 Inducibly Associates with TAK1 and MKK7 upon PMA-Ionomycin Stimulation
(A and B) Jurkat or JPM50.6 cells (33 107/sample) were stimulated with or without PMA (40 ng/ml) plus ionomycin (100 ng/ml). The cells were lysed
and precipitated with anti-TAK1 (A) or anti-MKK7 (B). Immunocomplexes or whole-cell lysates were subjected to SDS-PAGE and analyzed by immu-
noblot with indicated antibodies.
(C) Timed immunoprecipitation. Jurkat cells (12 3 107/time point) were stimulated with or without PMA plus ionomycin for 10 or 20 min and lyzed in
1 ml of lysis buffer. Each lysate was divided into four portions and immunoprecipitated with anti-JNK2, anti-MKK7, anti-TAK1, and anti-MALT1. The
immunocomplexes were subjected to SDS-PAGE and analyzed by western blot with indicated antibodies. Results are representative of 2–3 indepen-
dent experiments.cells (Figure 6B). Together, these results suggest that the
signal-dependent c-Jun accumulation is not mainly con-
trolled by NF-kB-dependent transcription, but is likely
controlled by the activated JNK2.
To investigate the mechanism of the signal-dependent
c-Jun accumulation, Jurkat T cells were treated with or
without cycloheximide andMG132, which inhibits the pro-
tein synthesis and protein degradation, respectively. We
found that the treatment with cycloheximide completely
inhibited CD3-CD28 costimulation-induced c-Jun accu-
mulation, whereas MG132 increased the basal and accu-
mulated amount of c-Jun protein (Figure 6C), suggesting
that CARMA1-dependent c-Jun accumulation is mainly
through new protein synthesis. In contrast, proteasome-
mediated degradation of c-Jun is mainly involved in main-
taining the steady-state amount of c-Jun. In addition,
although MG132 blocked CD3-CD28 costimulation-
induced IkBa degradation (Figure 6C, lanes 9–12), which
inhibited NF-kB activation, it did not inhibit CD3-CD28
costimulation-induced c-Jun accumulation, further sup-
porting our conclusion that the c-Jun accumulation is
not mainly controlled by NF-kB transcription factors
(Figure 6B).
To distinguish whether newly synthesized c-Jun was
controlled by the transcription or translation, Jurkat T cells
were treated with or without actinomycin D, which inhibits
the transcription, or actinomycin D plus MG132. We found
that the treatment with actinomycin D alone (Figure 6D,
lanes 5–8) or in combination with MG132 (Figure 6D, lanes9–12) completely inhibited CD3-CD28 costimulation-
induced c-Jun accumulation. These results indicate that
c-Jun accumulation is mainly controlled by the transcrip-
tion, but not translation or stabilizing protein. To further
confirm this finding, we compared c-Jun mRNA expres-
sion in Jurkat and JPM50.6 cells activated with CD3-28
for 30 and 60 min (Figure 6E). We found that CD3-28 cos-
timulation strongly increased c-Jun mRNA expression in
Jurkat but barely in JPM50.6 cells. Interestingly, basic
expression of c-Jun mRNA was also lower in JPM50.6
than in Jurkat cells. These results are consistent with
published data (Jaeschke et al., 2006).
Additionally, we found that the amount of JunBwas also
upregulated after CD3-CD28 costimulation in Jurkat cells
(Figure S4), and this accumulation of JunB was also
defected in CARMA1-deficient T cells (data not shown).
Although activation of JNK contributes to the activation
of AP-1 transcription factors, CARMA1-dependent JNK2
activation did not affect AP-1 activation (Figures 7A and
7B; Figure S5; Hara et al., 2003; Wang et al., 2002).
Together, our results indicate that CD3-CD28 costimula-
tion-induced JNK2 activation is not involved in the regula-
tion of AP-1 activation. Instead, CARMA1-dependent
JNK2 activation is involved in the accumulation of Jun
family of transcription factors through regulating the tran-
scription of these genes in lymphocytes.
To summarize our data, we propose a model of anti-
gen-induced activation of JNK (Figure 7C), in which PKC
mediates activation of both JNK1 and JNK2. However,Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc. 61
Immunity
CARMA1 and Bcl10 for JNK2 ActivationFigure 6. TCR-Induced c-Jun Accumulation Is Supressed in CARMA1-Deficient Cells
(A and B) Jurkat or JPM50.6 cells were stimulated with or without anti-CD3 and anti-CD28 antibodies (6 and 3 mg/ml, respectively) for various time
points (A), or NEMO-deficient Jurkat (JM4.5.2) cells or JPM50.6 cells were stimulated with or without PMA (40 ng/ml) plus anti-CD28 (3 mg/ml) for
various time points (B). Cell lysates were subjected to SDS-PAGE and immunoblot analysis with indicated antibodies.
(C and D) Jurkat T cells were preincubated with cycloheximide (CHX) (5 mg/ml), MG132 (5 mg/ml) (C), or actinomycin D (ActD) (5 mg/ml) (D) for 30 min,
and then stimulated with or without anti-CD3 plus anti-CD28. Cell lysates were subjected to SDS-PAGE and immunoblot analysis with indicated
antibodies.
(E) Cells were stimulated with or without anti-CD3 plus anti-CD28 (30 or 60min), and total RNA was isolated with RNA isolation kit followed by reverse
transcription polymerase chain reaction (RT-PCR). An aliquot (2 ml) of first-strand cDNA was used as a template in PCR amplifications of c-Jun and
GAPDH transcripts. Amplification products were resolved on a 1% agarose gel. Results are representative of three independent experiments.CARMA1 is required only for JNK2 activation. Activated
CARMA1 induces the oligomerization of Bcl10, and the
oligomerized Bcl10 functions as a scaffold molecule to
recruit MKK7 and TAK1, leading to activation of JNK2.
Therefore, some scaffold molecules, other than CARMA1
and Bcl10, are probably involved in assembling JNK1 with
MAP2K and MAP3K.
DISCUSSION
JNK family of kinases plays pivotal roles in cell activation,
differentiation, proliferation, and survival in response to
environmental stresses and cytokines (Davis, 2000;
Dong et al., 2002). JNK1 and JNK2 are the major forms
of JNK expressed ubiquitously (Gupta et al., 1996). Al-
though many lines of investigation have indicated that
JNK1 and JNK2 have functional differences and redun-
dancy, the upstream signaling pathway that selectively
activates JNK1 or JNK2 remains unknown. In this study,
we have revealed a regulatory mechanism of JNK activa-62 Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc.tion, in which different isoforms of JNK are regulated by
CARMA1-Bcl10-dependent and -independent mecha-
nisms in T cells.
Our results show that CD3-CD28 costimulation-
induced JNK2, but not JNK1, phosphorylation is selec-
tively defective in CARMA1-deficient Jurkat T cells and
primary T cells from CARMA1-deficient mice. In addition,
we showed that the phosphorylation status of JNK was
correlated with the activation of JNKs, in which the kinase
activity of JNK2 was dependent on CARMA1. We have
also performed the in vitro kinase assay to further confirm
that JNK1 could still be activated in CARMA1-deficient
cells. Therefore, our results strongly support the hypothe-
sis that CARMA1 ismainly involved in JNK2, but not JNK1,
activation. However, it is clear that JNK1 still receives
signal from T cell receptor, which may involve signaling
components other than CARMA1 and Bcl10.
It has been shown that each Jnk gene is also expressed
as 46 kDa (JNKp46) and 54 kDa (JNKp54) isoforms
because of the alternative splicing on their last exons,
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CARMA1 and Bcl10 for JNK2 ActivationFigure 7. AP-1 Activation Is Not Affected in Activated CARMA1-Deficient Cells
(A) Jurkat or JPM50.6 cells (13 107/sample) were preincubated with DMSO or MG132 for 30 min and then stimulated with or without anti-CD3 plus
anti-CD28 antibodies (6 and 3 mg/ml, respectively) for 30 min. Nuclear extracts were prepared and AP-1 binding activities were analyzed by electro-
phoretic mobility shift assay (EMSA) with 32P-labeled probes containing AP-1 or Oct-1 binding sites.
(B) Cells were transfected by electroporation with reporter plasmid encoding 4xAP-1-luc (10 mg) and pEF-Renilla-luc (200 ng). 20 hr later, the trans-
fected cells were either untreated or stimulated with anti-CD3 plus anti-CD28 (left) or PMA plus ionomycin (right) for 6 hr. Cell lysates were prepared
and luciferase activities were measured with Dual-Luciferase assay kits. AP-1 activities were determined by normalization of AP-1-dependent lucif-
erase to Renilla luciferase activity. Results are representative of two independent experiments performed in triplicate. Error bars indicate ± standard
deviation in triplicate experiments.
(C) The model of TCR-induced JNK phosphorylation. CD3-CD28 costimulation activates various proximal signaling components that lead to activa-
tion of PKC and CARMA1, which, in turn, recruits Bcl10 and induces its oligomerization. The activated (oligomerized) Bcl10 serves as a template for
TAK1, MKK7, and JNK2. Phosphorylated JNK2 and independently activated JNK1 led to accumulation of c-Jun and activation of AP-1.which results in an extra 43-residue tail at the C terminus
of p54 isoforms of JNK1, JNK2, and JNK3 (Gupta et al.,
1996; Kallunki et al., 1994). Of note, a small portion of
JNK1p54 isoform is expressed in T cells. However, this
portion of JNK1 (JNK1p54) is also defective after CD3-
CD28 costimulation, suggesting that the activation of
JNK1p54 isoform is also controlled by the CARMA1-
dependent pathway. Consistent with this possibility, ec-
topically expressed JNK1p54 in CARMA1-deficient Jurkat
T cells failed to respond to CD3-CD28 costimulation.
However, because JNK1p54 exists in a very small portion
in T cells, it will require more detailed analysis, such as
generating knock-in mice that express only the JNK1p54
or JNK1p46 isoform, for us to draw the more definite
conclusion regarding to the requirement of CARMA1 in
JNK1p54 activation.
Because CARMA1 is expressed in other hematopoietic
cells, we have also examined the JNK2 activation in
splenic B cells and bone marrow-derived mast cells
from CARMA1-deficient mice. We show that JNK2 activa-
tion is also dependent on CARMA1 in these cells after thestimulation with PMA plus ionomycin. Therefore, the
CARMA1-dependent regulation of JNK2 is not limited to
T cells, and, instead, a more general regulation in hemato-
pietic cells. However, it remains to be determined whether
JNK2 is also regulated differently from JNK1 in nonhema-
topietic cells that do not express CARMA1.
The CARMA1-dependent regulation of JNK2 is appar-
ently mediated through Bcl10, because JNK2 activation
is similarly defective in Bcl10-deficient cells. Previous
studies indicate that JNK is regulated through a family of
scaffold molecules, JIP (Morrison and Davis, 2003). Our
results suggest that Bcl10 functions as a JIP-like scaffold
molecule and inducibly associates with JNK2, MKK7, and
TAK1 in a CARMA1-dependent manner in lymphocytes.
The 43-residue tail at the C terminus of JNK2 is apparently
required for its association with Bcl10, which explains why
the CARMA1-Bcl10 complex specifically regulates p54,
but not p46, isoform of JNK. Interestingly, we find that
the oligomerization of Bcl10 through its CARD domain is
required for its association with JNK2. Therefore, our
current working model is that after stimulation, CARMA1Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc. 63
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Bcl10 functions as a scaffold molecule to recruit MKK7
and TAK1, leading to activation of JNK2. In contrast,
some scaffold molecules, other than CARMA1 and
Bcl10, are probably involved in assembling JNK1 with
MAP2K and MAP3K. Thus, it will be interesting to identify
the signaling components specifically connecting JNK1 to
antigen receptors.
Although several MAP3Ks, including MEKK1, MEKK2,
and MEKK3, have been implicated to play a role in JNK
activation in T cells, we can detect Bcl10 inducibly associ-
ated only with TAK1 but not other MAP3Ks (data not
shown). This result is consistent with the previous findings
that TAK1 plays a critical role in JNK activation in innate
and adaptive immune responses (Sato et al., 2005; Shim
et al., 2005). Moreover, a recent study (Wan et al., 2006)
demonstrates that partial depletion of TAK1 from CD4+
and CD8+ T cells selectively reduces phosphorylation of
JNK2. However, it is possible that other MAP3Ks may
be involved in the regulation of JNK1 activation, which is
consistent with the finding that JNK activation is partially
defective in T cells from transgenic mice expressing a
kinase-dead mutant of MEKK1 (Gao et al., 2004).
Activation of JNK has been shown to contribute to
the activation of AP-1 transcription factors. However,
CARMA1 deficiency does not affect AP-1 activation
(Hara et al., 2003; Wang et al., 2002). Therefore, the defect
of JNK2 is likely involved in the regulation of other biolog-
ical events. Recent studies suggest that JNK activation
controls c-Jun and JunB stability (Gao et al., 2004; Saba-
pathy and Wagner, 2004). Interestingly, we find that
CARMA1 deficiency leads to a defect of c-Jun accumula-
tion after CD3-CD28 costimulation. However, our results
suggest that the amount of c-Jun is mainly controlled by
a transcriptional regulation, instead of the protein stability,
after CD3-CD28 costimulation, although the proteasome-
mediated degradation is contributed to by the steady-
state amount of c-Jun and JunB. Our conclusions are
consistent with data demonstrating that JNK2 is a positive
regulator of c-Jun transcription in mouse embryo fibro-
blasts (Jaeschke et al., 2006).
Our study demonstrates that the defect of c-Jun accu-
mulation is not due to the failure of CARMA1-dependent
NF-kB activation, because c-Jun is still rapidly accumu-
lated after the stimulation in NEMO (IKKg)-deficient cells
that are defected in NF-kBactivation. In addition, although
the treatment of cells with MG132, a proteasome inhibitor,
blocked the degradation of IkBa and NF-kB activation,
CD3-CD28 costimulation could still effectively induce the
accumulation of c-Jun. Therefore, the accumulation of
c-Jun after CD3-CD28 costimulation is likely through
a JNK2-dependent, but NF-kB- and AP-1-independent,
mechanism.
In summary, our results provide genetic and biochemi-
cal evidence that JNK1 and JNK2 are differentially regu-
lated. The CARMA1-Bcl10 complex selectively regulates
JNK2 activation after TCR stimulation. Future studies are
required for determining how JNK2 activation affects
c-Jun accumulation and whether this type of differential64 Immunity 26, 55–66, January 2007 ª2007 Elsevier Inc.regulation of JNK1 and JNK2 occurs in nonhematopoietic
cells. Finally, it will be interesting to determine how JNK1
activation is regulated by other MAP3Ks, such as
MEKK1 after TCR stimulation.
EXPERIMENTAL PROCEDURES
Antibodies and Expression Plasmids
Antibodies specific for phospho-JNK (rabbit, cat. no. 9251) and anti-
bodies for total JNK, JNK2 (cat. no. 4672), c-Jun (60A8), phospho-
ERK1/2, and MKK7 were purchased from Cell Signaling Tech.
(Beverly, MA). Antibodies specific for JNK1 (C-17), ERK2 (C-14), Myc
(A14), HA (F-7), TAK1 (C-9), Bcl10 (H-197), MEKK2 (N-19), NEMO
(FL-419), and b-tubulin (D-10) were obtained from Santa Cruz Biotech.
(Santa Cruz, CA). Monoclonal antibodies against the C termini of
MALT1 were generated in the Genentech central production facility.
Rabbit and mouse TrueBlot HRP were purchased from Bioscience.
CD3 antibodies were from BD Biotechnology and CD28 from Caltag
Biotechnology (Burlingam, CA). CARMA1 antibodies were kindly pro-
vided by M. Thome (University of Lausanne, Switzerland). Expression
plasmids encoding Bcl10, Bcl10 (L47A), JNK2p54, and CARMA1 were
described previously (Kallunki et al., 1994;Wang et al., 2004; Yan et al.,
1999). CARMA1 was cloned into a mammalian expression vector,
pCMV-Tag2 (Stratagene), at BamHI and EcoRI sites. JNK2p46,
a JNK2p54 deletion mutant, was constructed by inserting a stop
codon that truncates the last 39 amino acids at the COOH terminus
of JNK2p54. Long form of JNK1 (JNK1p54) was cloned from Jurkat
T cells and inserted into the pRK6-Myc vector.
Cell Cultures and Stable Transfection
Jurkat T cells deficient in CARMA1 (JPM50.6) and cells reconstituted
with WT CARMA1 (50.6WT) were described earlier (Wang et al.,
2002, 2004). Cells were cultured in RPMI1640 medium supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml
streptomycin. Human embryo kidney 293 (HEK293) cells were main-
tained in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS and the antibiotics described above. Cells were grown in
5% CO2 at 37
C and passed every 3 days. Stable transfection of
JPM50.6 cells with truncated forms of CARMA1 was established by
lentiviral infection. Plasmids encoding FLAG-JNK1p46, HA-JNK2p54
and Myc-JNK1p54, were transfected into Jurkat and JPM50.6 cells
by electroporation with a gene pulser (Bio-Rad, Hercules, CA) at
250 V, 950 mF. HEK293 cells were transfected by the calcium phos-
phate coprecipitation method.
Western Blot and Coimmunoprecipitation
The cells were lysed in a buffer containing 50 mM HEPES (pH 7.4),
250 mM NaCl, 1% nonidet P-40, 1 mM EDTA, 1 mM Na3VO4, 1 mM
NaF, 1mMPMSF, 1mMdithiothreitol, and a protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany). The cell lysates were sub-
jected to SDS-PAGE and western blot or immunoprecipitated with
various antibodies (anti-JNK1, anti-JNK2, anti-Bcl10, anti-TAK1,
anti-MEKK2, anti-MKK7, or anti-HA). The immunoprecipitates were
washed with lysis buffer four times and eluted with 23 SDS loading
buffer. After boiling (4 min), the samples were fractionated on 10%
SDS-PAGE and transferred to nitrocellulose membranes. Immuno-
blots were incubated with specific primary antibodies followed by
HRP-conjugated secondary antibodies and were developed by the en-
hanced chemiluminescence method according to the manufacturer’s
protocol (Pierce, Rockford, IL). TrueBlot HRP (anti-rabbit and anti-
mouse IgG) was used to detect immunoprecipitated JNK2. This
reagent reduces the interference of 55 kDa IgG heavy chain in the
immunoprecititated complex.
In Vitro Kinase Assay
Endogenous or overexpressed JNK1 and JNK2 were immunoprecipi-
tated from cells treated with CD3 and CD28 antibodies for various time
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buffer and once with kinase buffer containing 10 mM HEPES
(pH 7.4), 1 mM MnCl2, 5 mM MgCl2, 12.5 mM glycerol-2-phosphate,
0.1 mM Na3VO4, 4 mM NaF, and 1 mM dithiothreitol. The reactions
with GST-c-Jun(1-79) were performed with 20 mM of cold ATP and
5 mCi of [g-32P]ATP in the kinase buffer at 30C for 30 min. The reac-
tions were stopped by adding 23 SDS loading buffer and the samples
were boiled for 4 min. The eluted proteins were fractionated on 10%
SDS-PAGE and transferred to nitrocellulose membranes, followed
by autoradiography.
ELISA
DuoSet IC Human Phospho-JNK2 (T183/Y185) ELISA kit was obtained
from R&D Systems (Minneapolis, MN). The amounts of phosphory-
lated JNK2 were measured in cell lysates according to the manufac-
turer’s protocol.
Purification and Stimulation of Murine T and B Cells
T cells were purified from total lymph node cells by mouse pan-T cell
purification kit (Miltenyi Biotech, Auburn, CA) according to the manu-
facturer’s recommendations. The purity of T cells was more than
95%based on anti-CD3 staining. B cells were purified fromRBC-lysed
splenocytes from WT, CARMA1 KO, and Bcl10 KO mice with anti-
CD43 magnetic beads according to the manufacturer’s recommenda-
tions (Miltenyi Biotech). The purity of B cells wasmore than 95%based
on B220/IgM staining. Purified cells were either unstimulated or stim-
ulated with PMA (20 ng/ml) plus ionomycin (200 ng/ml) for indicated
times. Cell lysates were subjected to SDS-PAGE and western blotting
analysis with indicated antibodies.
Generation and Stimulation of Bone Marrow-Derived Mast Cells
Bone marrow was harvested from the femur and tibia of WT and KO
mice and cultured in the complete RPMI-1640 medium supplemented
with IL-3 for 4–5 weeks to obtain bone marrow-derived mast cells
(BMMC). During the BMMC culture, nonadherent cells were recultured
in fresh medium containing IL-3 every week. Mast cell development
was confirmed by staining for FcRI and c-Kit receptor expression
and flow cytometric analysis. More than 95% cells obtained under
this culture condition were mast cells. These cells were either unstimu-
lated or stimulated with PMA (20 ng/ml) plus ionomycin (200 ng/ml) for
indicated time points. Cell lysates were subjected to SDS-PAGE and
western blotting analysis with indicated antibodies.
Mice
CARMA1 and Bcl10 null mice were described previously (Hara et al.,
2003; Xue et al., 2003). C57BL/6 mice were obtained from Harlan Lab-
oratory (Indianapolis, IN). All mice were used at 10–16 weeks of age.
Animals were housed under specific pathogen-free conditions at the
institutional animal facility. All the animal experiments were performed
in compliance with the institutional guidelines and according to the
protocol approved by Institutional Animal Use and Care Committee
of the University of Texas M.D. Anderson Cancer Center.
Supplemental Data
Five Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/26/1/55/DC1/.
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